References
- Atlas S, Touchette D, Agboola F, et al. Acute treatments for migraine: effectiveness and value. Institute for Clinical and Economic Review; 2020; [cited 2020 May 28]. Available from: https://icer-review.org/wp-content/uploads/2019/06/ICER_Acute-Migraine_Final-Evidence-Report_updated_05142020.pdf
- Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–745.
- Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241.
- Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II Randomized Clinical Trial. JAMA. 2019;322(19):1887–1898.
- Loo LS, Plato BM, Turner IM, et al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol. 2019;19(1):191.
- Lilly USA. REYVOWTM (lasmiditan) [prescribing information]. U.S. Food and Drug Administration; 2019; [cited 2020 Jun 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf